fabhalta Drug Patent Profile
✉ Email this page to a colleague
When do Fabhalta patents expire, and what generic alternatives are available?
Fabhalta is a drug marketed by Novartis and is included in one NDA. There are three patents protecting this drug.
This drug has fifty-seven patent family members in thirty-eight countries.
The generic ingredient in FABHALTA is iptacopan hydrochloride. One supplier is listed for this compound. Additional details are available on the iptacopan hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Fabhalta
Fabhalta will be eligible for patent challenges on December 5, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 5, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for fabhalta?
- What are the global sales for fabhalta?
- What is Average Wholesale Price for fabhalta?
Summary for fabhalta
International Patents: | 57 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Drug Prices: | Drug price information for fabhalta |
What excipients (inactive ingredients) are in fabhalta? | fabhalta excipients list |
DailyMed Link: | fabhalta at DailyMed |
![fabhalta drug patent expirations Drug patent expirations by year for fabhalta](/p/graph/s/t/fabhalta-patent-expirations.png)
![Drug Prices for fabhalta](/p/graph/drug-price/fabhalta.png)
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for fabhalta
Generic Entry Date for fabhalta*:
Constraining patent/regulatory exclusivity:
TREATMENT OF ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for fabhalta
fabhalta is protected by three US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of fabhalta is ⤷ Sign Up.
This potential generic entry date is based on TREATMENT OF ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting fabhalta
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 200 MG OF IPTACOPAN TWICE DAILY
Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting fabhalta
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | FABHALTA | iptacopan hydrochloride | CAPSULE;ORAL | 218276-001 | Dec 5, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Novartis | FABHALTA | iptacopan hydrochloride | CAPSULE;ORAL | 218276-001 | Dec 5, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Novartis | FABHALTA | iptacopan hydrochloride | CAPSULE;ORAL | 218276-001 | Dec 5, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Novartis | FABHALTA | iptacopan hydrochloride | CAPSULE;ORAL | 218276-001 | Dec 5, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Novartis | FABHALTA | iptacopan hydrochloride | CAPSULE;ORAL | 218276-001 | Dec 5, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for fabhalta
See the table below for patents covering fabhalta around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 297975 | צורה גבישית של lnp023 (Crystalline form of lnp023) | ⤷ Sign Up |
Hungary | E037510 | ⤷ Sign Up | |
Argentina | 096904 | DERIVADOS DE PIPERIDINIL-INDOL COMO INHIBIDORES DEL FACTOR DE COMPLEMENTO B Y USOS DE LOS MISMOS | ⤷ Sign Up |
China | 105579444 | Piperidinyl indole derivatives and their use as complement factor b inhibitors | ⤷ Sign Up |
Malaysia | 187454 | PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |